REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013
|
|
- Mavis Chandler
- 5 years ago
- Views:
Transcription
1 REFERENCE CODE GDHC1114CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - India Drug Forecast and Market Analysis to
2 Executive Summary Sales for Psoriasis in India 2012 We estimate the 2012 PsO drug sales to be $7.3m in India. By forecast end in, sales will increase to over $42.4m at a Compound Annual Growth Rate (CAGR) of 19.2%, due to the absence of pipeline therapies and biosimilars. This growth will be driven by: Figure below presents the PsO drug sales in India during the forecast period. Sales for Psoriasis in the India by Drug Class, Total: $7.33m Providing healthcare to all Indian citizens may increase drug uptake India s first home-grown brand will provide a new therapy and increase drug sales 100% Non-Steroidal Despite these drivers, the major barriers to the growth of the PsO market in India will include: 20% Total: $42.4m Alternative PsO therapies: biosimilars and Indian homeopathic medicine take away from branded drug sales Lack of IP guidelines hinders innovative drug uptake Downward pricing pressure limits drug sales growth Source: GlobalData Cytokine Inhibitor 80% Non-Steroidal Psoriasis - India Drug Forecast and Market Analysis to 2
3 Executive Summary What do the Physicians Think? Drug resistance and patients becoming refractory to therapies in less than three years have become main issues of discussion in the PsO world. The resistance issue will be an issue in the fiveyear [time] frame. We need alternative, possible alternative choices. The larger the number of available drugs, the better. [EU] key opinion leader, January 2013 The upcoming launches of the IL-17 inhibitors have KOLs extremely excited, as they hope to be able to put them to use early in the treatment paradigm. However, we encountered some physician experts who felt that the current pipeline would not unseat the established anti-tnf drugs. The use of biosimilars has also been a hot topic among dermatologists and other physicians who prescribe biologics for the warranted indications. However, there is a misconception as to the pricing of these biologic generics; we discovered mixed feelings among physicians regarding their presence due to manufacturing or pricing. I think it s an opportunity. This market is highly price-sensitive...when they come to the market; they will completely grab the market of the anti- TNFs, provided the prices are 30 to 50%. It is very significant If it s 20%, then I m disappointed. [EU] key opinion leader, January 2013 I m most excited about the antagonist IL-17. I find these drugs very effective and quite safe. I think they will probably have a role in the future. [EU] key opinion leader, January 2013 I don t think [the] new biologics coming will have an impact on the use of TNF inhibitors. [US] key opinion leader, December 2012 Psoriasis - India Drug Forecast and Market Analysis to 3
4 Table of Contents 1 Table of Contents 1 Table of Contents List of Tables List of Figures Introduction Catalyst Related Reports Upcoming Related Reports Disease Overview Etiology and Pathophysiology Etiology Pathophysiology Symptoms Disease Management Treatment Overview India Diagnosis Clinical Practice Competitive Assessment Overview Strategic Competitor Assessment Product Profiles Major Brands Psoriasis - India Drug Forecast and Market Analysis to 4
5 Table of Contents Taclonex (calcipotriene hydrate and betamethasone dipropionate) Methotrexate Sodium (numerous generic names) Minor Therapeutic Drug Classes Used in Psoriasis Non-Pharmacological Therapy Opportunity and Unmet Need Overview Unmet Needs Improved Drug Safety and Efficacy Profiles Biomarkers for Predicting Remission More Cost-Effective Therapies Through Oral Formulation and Biosimilars Education and Treatment of Psychological Factors Accompanying Psoriasis An Effective Biologic/Systemic Topical Therapy More Effective Treatment for Mild Psoriasis, Specifically UV Therapies Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis Opportunities Unmet Needs Gap Analysis Predictive Tools for Diagnosis and Treatment Target Specificity Topical Biologic/Systemic Therapeutic Options Helping Patients with Psychological Issues Associated with Psoriasis Pipeline Assessment Overview Promising Drugs in Clinical Development Psoriasis - India Drug Forecast and Market Analysis to 5
6 Table of Contents Alzumab (itolizumab) Phase II Pipeline Products Phase I Pipeline Products Biosimilars Pipeline Products Market Outlook India Forecast Key Events Drivers and Barriers Appendix Bibliography Abbreviations Methodology Forecasting Methodology Diagnosed Psoriasis Patients Percent Drug-Treated Patients Drugs Included in Each Therapeutic Class General Pricing Assumptions Individual Drug Assumptions Generic Erosion Pricing of Pipeline agents Physicians and Specialists Included in this Study Primary Research Prescriber Survey Psoriasis - India Drug Forecast and Market Analysis to 6
7 Table of Contents 9.7 About the Authors Analysts Global Head of Healthcare About GlobalData Disclaimer Psoriasis - India Drug Forecast and Market Analysis to 7
8 Table of Contents 1.1 List of Tables Table 1: Immune Cells Involved in Lesions Table 2: Symptoms of Psoriasis Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis Table 4: Treatment Guidelines for Psoriasis Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, Table 6: Leading Treatments for Psoriasis, Table 7: Product Profile Taclonex Table 8: Taclonex SWOT Analysis, Table 9: Product Profile Methotrexate Table 10: Methotrexate SWOT Analysis, Table 11: Summary of Minor Therapeutic Drug Classes for Psoriasis, Table 12: Overall Unmet Needs in Psoriasis Current Level of Attainment Table 13: Clinical Unmet Needs in Psoriasis Gap Analysis, Table 14: Psoriasis Phase Pipeline, Table 15: Comparison of Therapeutic Classes in Development for Psoriasis, Table 16: Product Profile Alzumab Table 17: Alzumab SWOT Analysis, Table 18: Global Sales Forecasts ($) for Alzumab, Table 19: Phase II Psoriasis Pipeline, Table 20: Phase I Psoriasis Pipeline, Table 21: Biosimilars Pipeline, Table 22: Sales Forecasts ($) for Psoriasis in India, Table 23: Key Events Impacting Sales for Psoriasis in India Psoriasis - India Drug Forecast and Market Analysis to 8
9 Table of Contents Table 24: Psoriasis Market in India Drivers and Barriers, Table 25: Physicians Surveyed, By Country Psoriasis - India Drug Forecast and Market Analysis to 9
10 Table of Contents 1.2 List of Figures Figure 1: Psoriatic Plaque on Elbow of Patient Figure 2: The Three Layers of the Skin and Associated Structures Figure 3: Healthy Skin Versus Psoriatic Skin Figure 4: BB-UVB Therapy Guidelines, According to the AAD Figure 5: NB-UVB Therapy Guidelines, According to the AAD Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, Figure 7: Estimated Sales of Biosimilars vs. Their Branded Counterparts in Psoriasis, Figure 8: Sales for Psoriasis in India by Drug Class, Psoriasis - India Drug Forecast and Market Analysis to 10
11 Introduction 2 Introduction 2.1 Catalyst The psoriasis market is currently very dynamic, with novel therapies awaiting approval, such as: Novartis interleukin-17 (IL-17) inhibitor, secukinumab Merck s interleukin-23 (IL-23) inhibitor, MK-3222 Celgene s phosphodiesterase-4 (PDE-4) inhibitor, apremilast These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. The impending patent cliff will allow for the emergence of biosimilars to all the marketed brands. Patent expiries begin in 2014 for the current market leaders, such as: Johnson & Johnson s Remicade (infliximab) AbbVie s (Abbott s pharmaceutical division) Humira (adalimumab) The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. India and China will also contribute to market growth as their populations obtain increasing access to Psoriasis (PsO) pharmacotherapy, but we expect slow growth, particularly in India. The challenges will be the crowded marketplace, comprising a highly-diversified field of therapies, with individual drugs struggling to distinguish themselves Amgen s Enbrel (etanercept) Johnson & Johnson s Stelara (ustekinumab) The drivers for market growth will also include affordable treatments throughout the world, as well as the push for long-term drug efficacy. India and China will also contribute to market growth as their populations obtain increasing access to PsO pharmacotherapy, but we expect slow growth, particularly in India. The challenges will be the crowded marketplace, comprising a highlydiversified field of therapies, with individual drugs struggling to distinguish themselves. Psoriasis - India Drug Forecast and Market Analysis to 11
12 Introduction 2.2 Related Reports GlobalData (2013). Psoriasis US Drug Forecast and Market Analysis to, GDHC1106CFR. GlobalData (2013). Psoriasis France Drug Forecast and Market Analysis to, GDHC1107CFR. GlobalData (2013). Psoriasis Germany Drug Forecast and Market Analysis to, GDHC1108CFR. GlobalData (2013). Psoriasis Italy Drug Forecast and Market Analysis to, GDHC1109CFR. GlobalData (2013). Psoriasis Spain Drug Forecast and Market Analysis to, GDHC1110CFR. GlobalData (2013). Psoriasis United Kingdom Drug Forecast and Market Analysis to, GDHC1111CFR. GlobalData (2013). Psoriasis Japan Drug Forecast and Market Analysis to, GDHC1112CFR. GlobalData (2013). Psoriasis China Drug Forecast and Market Analysis to, GDHC1113CFR. GlobalData (2013). Psoriasis India Drug Forecast and Market Analysis to, GDHC1114CFR. GlobalData (2013). Enbrel (Psoriasis) Forecast and Market Analysis to, GDHC1177DFR. GlobalData (2013). Humira (Psoriasis) Forecast and Market Analysis to, GDHC1178DFR. GlobalData (2013). Remicade (Psoriasis) Forecast and Market Analysis to, GDHC1179DFR. Psoriasis - India Drug Forecast and Market Analysis to 12
13 Introduction GlobalData (2013). Stelara (Psoriasis) Forecast and Market Analysis to, GDHC1180DFR. GlobalData (2013). Brodalumab (Psoriasis) Forecast and Market Analysis to, GDHC1170DFR. GlobalData (2013). Secukinumab (Psoriasis) Forecast and Market Analysis to, GDHC1171DFR. GlobalData (2013). Ixekizumab (Psoriasis) Forecast and Market Analysis to, GDHC1172DFR. GlobalData (2013). MK-3222 (Psoriasis) Forecast and Market Analysis to, GDHC1173DFR. GlobalData (2013). Xeljanz (Psoriasis) Forecast and Market Analysis to, GDHC1174DFR. GlobalData (2013). Apremilast (Psoriasis) Forecast and Market Analysis to, GDHC1175DFR. GlobalData (2013). Alzumab (Psoriasis) Forecast and Market Analysis to, GDHC1176DFR. GlobalData (2013). Psoriasis Current and Future Players. GDHC1015FPR. Psoriasis - India Drug Forecast and Market Analysis to 13
14 Appendix 9.8 About GlobalData GlobalData is a leading global provider of business intelligence in the healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in drug research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports, and forecasts. Our analysis is supported by a 24/7 client support and analyst team. GlobalData has offices in New York, Boston, London, India, and Singapore. 9.9 Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher, GlobalData. Psoriasis - India Drug Forecast and Market Analysis to 89
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1174DFR PUBLICATION DATE M AY 2013 XELJANZ (PSORIASIS) - Executive Summary Table below presents key metrics for Xeljanz (tofacitinib) in seven of the nine major pharmaceutical markets
More informationREFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1170DFR PUBLICATION DATE M AY 2013 BRODALUMAB (PSORIASIS) - Executive Summary Table below presents key metrics for brodalumab in seven of the nine major pharmaceutical markets covered
More informationRituxan (Rheumatoid Arthritis)
Rituxan (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1008DFR / Published November 2012 Executive Summary Rituxan: Key Metrics in Rheumatoid Arthritis Markets 2012 Rituxan Sales Total 7 MM $835m
More informationActemra (Rheumatoid Arthritis)
Actemra (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1007DFR / Published November 2012 Executive Summary Actemra: Key Metrics in Rheumatoid Arthritis Markets 2012 Actemra Sales Total 7 MM $355m
More informationOrencia (Rheumatoid Arthritis)
Orencia (Rheumatoid Arthritis) Forecast and Market Analysis GDHC1006DFR / Published November 2012 Executive Summary Orencia: Key Metrics in Rheumatoid Arthritis Markets 2012 Orencia Sales Total 7 MM $831m
More informationPharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationKeppra (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1061DFR Publication Date: February 2013
Keppra (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1061DFR Publication Date: February 2013 Executive Summary Keppra (levetiracetam) Key Metrics in the Nine Major Pharmaceutical
More informationREFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC294DFR PUBLICATION DATE NOVEMBER 2013 PROTOPIC (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Protopic in the nine major pharmaceutical markets
More informationLUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND LUPUS NEPHRITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC279DFR PUBLICATION DATE OCTOBER 2013 LUPUZOR (SYSTEMIC LUPUS ERYTHEMATOSUS AND Executive Summary Table below presents the key metrics of Lupuzor for Systemic Lupus Erythematosus (SLE)
More informationREFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC296DFR PUBLICATION DATE NOVEMBER 2013 DUPILUMAB (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Dupilumab in the nine major pharmaceutical markets
More informationLamictal (Epilepsy) Forecast and Market Analysis to Reference Code: GDHC1062DFR Publication Date: February 2013
Lamictal (Epilepsy) Forecast and Market Analysis to 2022 Reference Code: GDHC1062DFR Publication Date: February 2013 Executive Summary Lamictal (lamotrigine) Key Metrics in the Nine Major Pharmaceutical
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More informationREFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC509DFR PUBLICAT ION DATE DECEMBER 2014 MAVRILIMUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Mavrilimumab in the 10MM Rheumatoid Arthritis
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More informationREFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
More informationREFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1062CFR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE - JAPAN DRUG Executive Summary Sales for Chronic Heart Failure in the Japan The Japan Chronic heart failure (CHF) therapeutics
More informationREFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC501DFR PUBLICAT ION DATE DECEMBER 2014 XELJANZ (TOFACITINIB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Xeljanz (tofacitinib) in the 10MM
More informationREFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC497DFR PUBLICAT ION DATE DECEMBER 2014 ORENCIA (ABATACEPT) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Orencia (abatacept) in the 10MM (US,
More informationREFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
More informationREFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013
REFERENCE CODE GDHC1087DFR PUBLICATION DATE JUNE 2013 Executive Summary Diovan (valsartan): Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Market Sales US - Diovan 5EU - Diovan Japan - Diovan
More informationREFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC224CFR PUBLICAT ION DATE FEBRUARY 2014 SCHIZOPHRENIA Executive Summary Schizophrenia Sales in the US, 2012 The combined sales of medications carrying an indication in schizophrenia in
More informationREFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC519DFR PUBLICAT ION DATE DECEMBER 2014 LOTRONEX (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Prometheus Lotronex for irritable bowel syndrome
More informationREFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC525DFR PUBLICAT ION DATE DECEMBER 2014 TENAPANOR (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of AstraZeneca/Ardelyx s tenapanor for Irritable
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationREFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC366DFR PUBLICAT ION DATE FEBRUARY 2014 CARIPRAZINE (SCHIZOPHRENIA) Executive Summary Table below provides a summary of the key metrics for Cariprazine in the seven major pharmaceutical
More informationKaletra (HIV) Forecast and Market Analysis to GDHC1051DFR/ Published January 2013
Kaletra (HIV) Forecast and Market Analysis to 2022 GDHC1051DFR/ Published January 2013 Executive Summary Kaletra Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US - Kaletra 5EU
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationDry Eye Syndrome. US Drug Forecast and Market Analysis to GDHC1115CFR / Published May 2013
Dry Eye Syndrome US Drug Forecast and Market Analysis to 2022 GDHC1115CFR / Published May 2013 Executive Summary Sales for Dry Eye Syndrome in the US The Dry Eye Syndrome (DES) market in the US will grow
More informationACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC498DFR PUBLICATION DATE DECEM BER 2014 ACTEMRA/ROACTEMRA (TOCILIZUMAB) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Actemra/RoActemra (tocilizumab)
More informationREFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC426DFR PUBLICAT ION DATE M AY 2014 CARIPRAZINE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for cariprazine in the Major Depressive Disorder (MDD)
More informationREFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC425DFR PUBLICAT ION DATE M AY 2014 BREXPIPRAZOLE (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for brexpiprazole in the Major Depressive Disorder
More informationREFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC521DFR PUBLICAT ION DATE DECEMBER 2014 ELUXADOLINE (IRRITABLE BOWEL SYNDROME) Executive Summary The Table below presents the key metrics of Furiex (Actavis) s eluxadoline for Irritable
More informationREFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC423DFR PUBLICAT ION DATE M AY 2014 ABILIFY (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Abilify in the seven major pharmaceutical markets
More informationREFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC420DFR PUBLICAT ION DATE M AY 2014 FETZIMA (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Fetzima in the seven major pharmaceutical markets
More informationREFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC518DFR PUBLICAT ION DATE DECEMBER 2014 LINZESS (IRRITABLE BOWEL SYNDROME) - Executive Summary The Table below presents the key metrics of Ironwood/Actavis/Almirall/Astellas Linzess for
More informationREFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC504DFR PUBLICAT ION DATE DECEMBER 2014 SARILUMAB (RHEUMATOID ARTHRITIS) Executive Summary The table below presents the key metrics for Sarilumab in the 10MM Rheumatoid Arthritis (RA)
More informationREFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC502DFR PUBLICAT ION DATE DECEMBER 2014 IGURATIMOD/T-614 (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Iguratimod/T-614 in the 10MM (US, France,
More informationREFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC496DFR PUBLICAT ION DATE DECEMBER 2014 CIMZIA (CERTOLIZUMAB PEGOL) (RHEUMATOID ARTHRITIS) - Executive Summary The table below provides the key metrics for Cimzia (certolizumab pegol)
More informationREFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC422DFR PUBLICAT ION DATE M AY 2014 BRINTELLIX (MAJOR DEPRESSIVE DISORDER) - Executive Summary Table below presents the key metrics for Brintellix in the seven major pharmaceutical markets
More informationCyclokat (Dry Eye Syndrome)
Cyclokat (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC191DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Cyclokat in the major pharmaceuticals
More informationREFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1161DFR PUBLICAT ION DATE SEPTEMBER 2013 MENOMUNE (MENINGOCOCCAL VACCINES) - Executive Summary Menomune: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU
More informationPegIntron (Hepatitis C Virus) Forecast and Market Analysis to GDHC1143DFR / Published May 2013
PegIntron (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1143DFR / Published May 2013 Executive Summary PegIntron (peginterferon alfa-2b) Key Metrics in the Major Pharmaceutical Markets 2012
More informationREFERENCE CODE GDHC361DFR PUBLICAT ION DATE FEBRUARY 2014 INVEGA (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC361DFR PUBLICAT ION DATE FEBRUARY 2014 INVEGA (SCHIZOPHRENIA) Executive Summary Invega : Key Metrics in the Seven Major Pharmaceutical Markets, 2012 2022 2012 Market Sales US 5EU Japan
More informationREFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC392DFR PUBLICATION DATE M ARCH 2014 STALEVO/COMTAN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Stalevo/Comtan in the 8MM Parkinson
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationREFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC1155DFR PUBLICAT ION DATE SEPTEMBER 2013 NIMENRIX (MENINGOCOCCAL VACCINES) Executive Summary Nimenrix: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Market Sales US 5EU Japan
More informationREFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationSofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to GDHC1150DFR / Published May 2013
Sofosbuvir and Sofosbuvir/Ledipasvir (Hepatitis C Virus) Forecast and Market Analysis to 2022 GDHC1150DFR / Published May 2013 Executive Summary Sofosbuvir and Sofosbuvir/Ledipasvir: Key Metrics in Nine
More informationREFERENCE CODE GDHC357DFR PUBLICAT ION DATE FEBRUARY 2014 CLOZARIL (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC357DFR PUBLICAT ION DATE FEBRUARY 2014 CLOZARIL (SCHIZOPHRENIA) Executive Summary Clozaril: Key Metrics in the Seven Major Pharmaceutical Markets, 2012 2022 2012 Market Sales US 5EU
More informationREFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013
REFERENCE CODE GDHC013POA PUBLICAT ION DATE DECEM BER 2013 ACUTE ISCHEMIC STROKE - Executive Summary Acute Ischemic Stroke: Key Metrics in Six Major Pharmaceutical Markets 2012 Epidemiology Prevalent Cases
More informationREFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC238DFR PUBLICAT ION DATE JULY 2013 EMPAGLIFLOZIN (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Empagliflozin for Type 2 diabetes in the 10 major pharmaceutical
More informationREFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC378DFR PUBLICAT ION DATE M ARCH 2014 BOTOX (MIGRAINE) - Executive Summary Botox: Key Metrics in the 7MM* for Migraine, 2012-2023 2012 Market Sales US $434.3m 5 EU $68.3m Japan Total
More informationREFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC386DFR PUBLICAT ION DATE M ARCH 2014 GARDASIL (PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Gardasil: Key Metrics in Nine Major
More informationREFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC391DFR PUBLICAT ION DATE M ARCH 2014 DUODOPA (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Duodopa in the 8MM Parkinson s Disease
More informationREFERENCE CODE GDHC356DFR PUBLICAT ION DATE FEBRUARY 2014 SAPHRIS (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC356DFR PUBLICAT ION DATE FEBRUARY 2014 SAPHRIS (SCHIZOPHRENIA) FORECAST AND MARKET ANALYSISTO 2022 Executive Summary Saphris: Key Metrics in the Seven Major Pharmaceutical Markets, 2012
More informationREFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC183CFR PUBLICAT ION DATE NOVEM BER 2013 ATOPIC DERMATITIS Executive Summary Sales for Atopic Dermatitis 2012 in US The US Atopic dermatitis market was worth approximately $1.35 billion
More informationREFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC397DFR PUBLICAT ION DATE M ARCH 2014 NOURIAST (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Nouriast in the 8MM Parkinson s Disease
More informationDry Eye Syndrome - Current and Future Players. GDHC1016FPR / Published May 2013
Dry Eye Syndrome - Current and Future Players GDHC1016FPR / Published May 2013 Executive Summary Significant growth is expected in the DES market from 2012-2022. GlobalData estimates 2012 DES therapeutic
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationREFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC395DFR PUBLICAT ION DATE M ARCH 2014 APOKYN (PARKINSON S DISEASE) - Executive Summary The table below provides a summary of the key metrics for Apokyn in the 8MM Parkinson s Disease
More informationREFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC282DFR PUBLICATION DATE OCTOBER 2013 BELVIQ (OBESITY) - Executive Summary Below table provides a summary of Belviq for obesity in the nine major pharmaceutical markets during the forecast
More informationREFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC398DFR PUBLICAT ION DATE M ARCH 2014 SAFINAMIDE (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Safinamide in the 8MM Parkinson s disease (PD)
More informationREFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC233DFR PUBLICAT ION DATE JULY 2013 ALBIGLUTIDE (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Albiglutide for Type 2 diabetes in the 10 major pharmaceutical
More informationREFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
More informationDiquas (Dry Eye Syndrome)
Diquas (Dry Eye Syndrome) Forecast and Market Analysis to 2022 GDHC187DFR / Published July 2013 Executive Summary Below table provides a summary of the key metrics for Diquas in the global Dry Eye Syndrome
More informationREFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC401DFR PUBLICAT ION DATE M ARCH 2014 RYTARY/IPX066 (PARKINSON S DISEASE) - Executive Summary The table below summarizes the key metrics for Rytary/IPX066 in the 8MM Parkinson s disease
More informationREFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC220DFR PUBLICAT ION DATE JULY 2013 JANUVIA (TYPE 2 DIABETES) - Executive Summary Below table provides a summary of Januvia for Type 2 diabetes in the 10 major pharmaceutical markets
More informationREFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Parkinson s Disease in Japan Market The Parkinson
More informationREFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 ATRASENTAN (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC321DFR PUBLICAT ION DATE DECEMBER 2013 Executive Summary The table below presents a summary of the key metrics for Atrasentan (Microvascular Complications for Diabetes) in the seven
More informationREFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 FASIGLIFAM (TYPE 2 DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC241DFR PUBLICAT ION DATE JULY 2013 Executive Summary Fasiglifam (TAK-875): Key Metrics in the 10 Major Pharmaceutical Markets* 2022 Market Sales US $508m 5EU $127m Japan $30m China $341m
More informationREFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1042FPR PUBLICAT ION DATE DECEMBER 2014 IRRITABLE BOWEL SYNDROME Executive Summary Sales of Irritable Bowel Syndrome Market The Irritable Bowel Syndrome (IBS) market in the 7MM (US,
More informationREFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC317DFR PUBLICAT ION DATE DECEMBER 2013 LUCENTIS Executive Summary The table below presents a summary of the key metrics for Lucentis (Microvascular Complications for Diabetes) for recombinant
More informationREFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA (MICROVASCULAR COMPLICATIONS OF DIABETES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC319DFR PUBLICAT ION DATE DECEMBER 2013 EYLEA Executive Summary The table below presents a summary of the key metrics for Eylea (Microvascular Complications for Diabetes) for recombinant
More informationREFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC407DFR PUBLICAT ION DATE APRIL 2014 QUTENZA (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Qutenza in the 7MM neuropathic pain markets during
More informationREFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC406DFR PUBLICAT ION DATE APRIL 2014 LIDODERM/VERSATIS (NEUROPATHIC PAIN) - Executive Summary Table below provides a summary of the key metrics for Lidoderm/Versatis in the 7MM neuropathic
More informationREFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Sales for Parkinson s Disease in the US The Parkinson s disease market in the
More informationREFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1033FPR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - CURRENT AND FUTURE PLAYERS Executive Summary Sales for Parkinson s Disease Market The Parkinson s disease market in the US,
More informationCytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Reference Code: GDHC504PRT Publication Date: January 2013 Cytomegalovirus Infections: Key Metrics in Seven Major Pharmaceutical Markets 2012 Epidemiology* Prevalent population (CMV prevalent cases in general
More informationREFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC239CFR PUBLICAT ION DATE APRIL 2014 NEUROPATHIC PAIN - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Neuropathic Pain (NP) in the US The US NP market was valued
More informationREFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1032FPR PUBLICAT ION DATE M ARCH 2014 PROPHYLACTIC HUMAN PAPILLOMAVIRUS VACCINES - Executive Summary Human PapillomaVirus (HPV) Vaccine Sales Expected to Grow Modestly During the Forecast
More informationREFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC334DFR PUBLICAT ION DATE J ANU ARY 2014 ENGERIX-B (PROPHYLACTIC HEPATITIS B VIRUS VACCINES) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The table below provides a summary
More informationREFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC109PIDR PUBLICAT ION DATE MAY 2015 FIBROMYALGIA GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Fibromyalgia: Key Metrics in Seven Major Pharmaceutical Markets, 2013
More informationREFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC482DFR PUBLICAT ION DATE OCTOBER 2014 EYLEA (MACULAR EDEMA AND MACULAR DEGENERATION) - Executive Summary Table below presents the key metrics of Eylea for macular edema (ME) and age-related
More informationREFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER046 PUBLICAT ION DATE OCTOBER 2013 DIABETIC FOOT ULCERS - Executive Summary Diabetic foot ulcers (DFUs) are a major complication of diabetes that occurs as a result of trauma to or
More informationREFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 PARKINSON S DISEASE - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER043 PUBLICAT ION DATE NOVEMBER 2013 Executive Summary Parkinson s disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer s
More informationEpilepsy Global Drug Forecast and Market Analysis. Reference Code: GDHC35PIDR Publication Date: January 2013
Epilepsy Global Drug Forecast and Market Analysis Reference Code: GDHC35PIDR Publication Date: January 2013 Executive Summary Epilepsy: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology
More informationREFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - Executive Summary Meningococcal Vaccines: Key Metrics in the Nine Major Pharmaceutical Markets 2012 Epidemiology Targeted
More informationREFERENCE CODE GDHC68PIDR PUBLICATION DATE JANUARY 2014 PROPHYLACTIC HEPATITIS B VIRUS VACCINES - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC68PIDR PUBLICATION DATE JANUARY 2014 PROPHYLACTIC HEPATITIS B VIRUS VACCINES - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Prophylactic HBV Vaccines: Key Metrics
More informationREFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER052 PUBLICAT ION DATE NOVEMBER 2013 DIABETIC NEPHROPATHY - Executive Summary Diabetic nephropathy is one of the microvascular complications of diabetes, along with diabetic neuropathy
More informationREFERENCE CODE GDHC45PIDR PUBLICATION DATE JUNE 2013
REFERENCE CODE GDHC45PIDR PUBLICATION DATE JUNE 2013 CHRONIC HEART FAILURE Executive Summary CHF: Key Metrics in the Seven Major Pharmaceutical Markets* 2012 Epidemiology CHF prevalent population 2012
More informationNONALCOHOLIC STEATOHEPATITIS (NASH) - OPPORTUNITY ANALYSIS AND FORECASTS TO EVENT-DRIVEN UPDATE
REFERENCE CODE GDHC034POA PUBLICAT ION DATE MARCH 2014 NONALCOHOLIC STEATOHEPATITIS (NASH) - - EVENT-DRIVEN UPDATE Executive Summary NASH: Key Metrics in Six Major Pharmaceutical Markets 2012 Epidemiology
More informationAtopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024
Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 Atopic Dermatitis - Japan Drug Forecast and Market Analysis to 2024 BioPortfolio has been marketing business and market research reports
More informationREFERENCE CODE GDHC028POA PUBLICAT ION DATE DECEM BER 2014
REFERENCE CODE GDHC028POA PUBLICAT ION DATE DECEM BER 2014 ACROMEGALY AND GIGANTISM Executive Summary Table below presents the key metrics for acromegaly and gigantism in the six major pharmaceutical markets
More informationREFERENCE CODE GDHCER PUBLICAT ION DATE M AY 2015 GLAUCOMA EPIDEMIOLOGY FORECAST TO 2023
REFERENCE CODE GDHCER081-15 PUBLICAT ION DATE M AY 2015 GLAUCOMA Executive Summary Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye s optic nerve, resulting in progressive,
More informationREFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - EPIDEMIOLOGY FORECAST TO 2022
REFERENCE CODE GDHCER022 PUBLICAT ION DATE AUGUST 2013 OVERWEIGHT AND OBESITY - Executive Summary Obesity is an escalating global public health problem that has reached pandemic proportions. It is caused
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More information